Inventor · disambiguated record
Matthew Hardy
Also filed as: HARDY MATTHEW · HARDY MATTHEW P · HARDY MATTHEW PHILIP
8 granted patents·15 pending applications·36 citations·filing 2004–2024
83Inventor score
Files withCSL LTD16CSL Behring Lengnau AG2CSL Innovation Pty Ltd2NASH ANDREW DONALD1POPULATION COUNCIL INC1
Top patents by PatentIndex Score
23 records- 0192US9340618B2IL-11R binding proteinsCSL LTD·Filed 2014·Granted May 17, 2016·22 cites·15 claims
- 0286US2025051462A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2024·Application pending·0 cites
- 0385US11840573B2CD131 binding proteins and uses thereofCSL LTD·Filed 2020·Granted Dec 12, 2023·1 cites·20 claims
- 0482US10894834B2CD131 binding proteinsCSL LTD·Filed 2016·Granted Jan 19, 2021·2 cites·5 claims
- 0582US9193793B2Antibodies against G-CSFR and uses thereofNASH ANDREW DONALD·Filed 2012·Granted Nov 24, 2015·6 cites·21 claims
- 0680US9796782B2Fibronectin III domain of IL-11RαCSL LTD·Filed 2015·Granted Oct 24, 2017·3 cites·14 claims
- 0777US2024174757A1Cd131 binding proteins and uses thereofCSL LTD·Filed 2023·Application pending·0 cites
- 0873US10806774B2Mutated truncated von Willebrand FactorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·42 claims
- 0971US12071484B2Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded proteinCSL LTD·Filed 2020·Granted Aug 27, 2024·0 cites·14 claims
- 1070US10808023B2Mutated von Willebrand factorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·22 claims
- 1163US2019055313A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2018·Application pending·0 cites
- 1262US2019185573A1Agents that neutralize il-3 signalling and uses thereofCSL LTD·Filed 2018·Application pending·0 cites
- 1361US2016046718A1Agents that neutralize il-3 signalling and uses thereofCSL LTD·Filed 2014·Application pending·0 cites
- 1459US2017226214A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2017·Application pending·0 cites
- 1558US2018208661A1Agents that neutralize il-3 signalling and uses thereofCSL LTD·Filed 2017·Application pending·0 cites
- 1655US2016031998A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2015·Application pending·0 cites
- 1752US2016031996A1Anti il-3r alpha agents and uses thereofCSL LTD·Filed 2014·Application pending·0 cites
- 1851US2007219172A1Selective testicular 11beta-HSD inhibitors for the treatment of hypergonadism associated disorders and modulation of fertilityPOPULATION COUNCIL INC·Filed 2006·Application pending·0 cites
- 1948US2005020550A1Selective testicular 11beta-HSD inhibitors and methods of use thereofFiled 2004·Application pending·0 cites
- 2048US2018244786A1Anti il-3r alpha agents and uses thereofCSL LTD·Filed 2017·Application pending·0 cites
- 2147US2022305133A1Soluble Complement Receptor Type 1 Variant Conjugates and Uses ThereofCSL Innovation Pty Ltd·Filed 2020·Application pending·0 cites
- 2246US2022332804A1Complement C2 Binding Proteins and Uses ThereofCSL Innovation Pty Ltd·Filed 2020·Application pending·0 cites
- 2342US2021238238A1Soluble complement receptor type i variants and uses thereofCSL LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Hardy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →